RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Newron Pharmaceuticals SpA Stock

Newron Pharmaceuticals SpA Liabilities 2024

Newron Pharmaceuticals SpA Liabilities

55.77 M EUR

Ticker

NWRN.SW

ISIN

IT0004147952

WKN

A0LF18

In 2024, Newron Pharmaceuticals SpA's total liabilities amounted to 55.77 M EUR, a 8.88% difference from the 51.22 M EUR total liabilities in the previous year.

Newron Pharmaceuticals SpA Aktienanalyse

What does Newron Pharmaceuticals SpA do?

Newron Pharmaceuticals SpA is an international biopharmaceutical company specializing in the development of novel products for the treatment of central nervous system (CNS) disorders. The company is headquartered in Italy and is listed on the SIX Swiss Exchange. The history of Newron Pharmaceuticals SpA dates back to 1996 when it was founded by a team of experienced pharmaceutical experts. Since then, the company has become a leading player in the development of therapies for rare neurological disorders. The focus is particularly on diseases such as Parkinson's and Rett syndrome, as well as other neurological disorders. Newron Pharmaceuticals SpA's business model is based on the research and development of novel drugs in the field of the central nervous system. The company typically conducts research and development in its own laboratories and collaborates closely with external experts and institutions to develop innovative therapies. The goal is to develop patient-oriented, innovative drugs and successfully bring them to market. The company has several product candidates in various stages of development, including Xadago® (Safinamide), an approved drug for the treatment of Parkinson's. Similarly, an orally administered drug is being tested in phase III of clinical development with the aim of improving motor symptoms in Parkinson's. Another important product candidate of Newron Pharmaceuticals SpA is Sarizotan, an innovative drug for the treatment of Rett syndrome, a rare neurological disease that primarily affects girls. The company has entered into a partnership with the American company Rett Syndrome Research Trust (RSRT) to promote further development of the drug. In addition to researching and developing new drugs, Newron also actively works on advancing existing treatment approaches. For example, collaborations with academic institutions are used to incorporate new knowledge from the fields of molecular biology and genetics to further expand existing therapeutic approaches. The company follows an integrative approach, focusing on collaboration between research and development teams, clinical experts, patient organizations, and regulatory authorities. The goal is to treat patients with novel and effective therapies. Overall, Newron Pharmaceuticals SpA is an internationally operating biopharmaceutical company dedicated to researching and developing novel therapies in the field of the central nervous system. Through its innovative research and development activities and close collaboration with experts, institutions, and patient organizations, the company significantly contributes to the advancement of treatment options for neurological disorders. Newron Pharmaceuticals SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Newron Pharmaceuticals SpA's Liabilities

Newron Pharmaceuticals SpA's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Newron Pharmaceuticals SpA's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Newron Pharmaceuticals SpA's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Newron Pharmaceuticals SpA's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Newron Pharmaceuticals SpA’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Newron Pharmaceuticals SpA stock

What is the level of liabilities of Newron Pharmaceuticals SpA this year?

Newron Pharmaceuticals SpA has a debt balance of 55.77 M EUR this year.

What were the liabilities of Newron Pharmaceuticals SpA compared to the previous year?

The liabilities of Newron Pharmaceuticals SpA have increased by 8.88% increased compared to the previous year.

What are the consequences of high debt for investors of Newron Pharmaceuticals SpA?

High liabilities can pose a risk for investors of Newron Pharmaceuticals SpA, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Newron Pharmaceuticals SpA?

Low liabilities mean that Newron Pharmaceuticals SpA has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Newron Pharmaceuticals SpA affect the company?

An increase in liabilities of Newron Pharmaceuticals SpA can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Newron Pharmaceuticals SpA affect the company?

A decrease in the liabilities of Newron Pharmaceuticals SpA can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Newron Pharmaceuticals SpA?

Some factors that can influence the liabilities of Newron Pharmaceuticals SpA include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Newron Pharmaceuticals SpA so important for investors?

The liabilities of Newron Pharmaceuticals SpA are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Newron Pharmaceuticals SpA take to modify the liabilities?

To change its liabilities, Newron Pharmaceuticals SpA can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Newron Pharmaceuticals SpA pay?

Over the past 12 months, Newron Pharmaceuticals SpA paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Newron Pharmaceuticals SpA is expected to pay a dividend of 0 EUR.

What is the dividend yield of Newron Pharmaceuticals SpA?

The current dividend yield of Newron Pharmaceuticals SpA is .

When does Newron Pharmaceuticals SpA pay dividends?

Newron Pharmaceuticals SpA pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Newron Pharmaceuticals SpA?

Newron Pharmaceuticals SpA paid dividends every year for the past 0 years.

What is the dividend of Newron Pharmaceuticals SpA?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Newron Pharmaceuticals SpA located?

Newron Pharmaceuticals SpA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Newron Pharmaceuticals SpA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Newron Pharmaceuticals SpA from 10/28/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.

When did Newron Pharmaceuticals SpA pay the last dividend?

The last dividend was paid out on 10/28/2024.

What was the dividend of Newron Pharmaceuticals SpA in the year 2023?

In the year 2023, Newron Pharmaceuticals SpA distributed 0 EUR as dividends.

In which currency does Newron Pharmaceuticals SpA pay out the dividend?

The dividends of Newron Pharmaceuticals SpA are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Newron Pharmaceuticals SpA

Our stock analysis for Newron Pharmaceuticals SpA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Newron Pharmaceuticals SpA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.